7,722 Shares in AbbVie Inc. $ABBV Purchased by Titan Investment Solutions Ltd

Titan Investment Solutions Ltd purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 7,722 shares of the company’s stock, valued at approximately $1,764,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Chelsea Counsel Co. bought a new position in AbbVie during the third quarter worth about $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie during the fourth quarter worth about $28,000. Westend Capital Management LLC bought a new position in AbbVie during the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the third quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.2%

Shares of NYSE:ABBV opened at $227.54 on Friday. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81. The stock has a market cap of $402.02 billion, a PE ratio of 112.09, a P/E/G ratio of 0.69 and a beta of 0.32. The business has a 50 day moving average of $211.05 and a 200-day moving average of $219.07.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. Equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Canaccord Genuity Group boosted their price objective on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.